Literature DB >> 11439313

Antihypertensive efficacy of amlodipine in children with chronic kidney diseases.

R O von Vigier1, L M Franscini, N D Bianda, R Pfister, C Casaulta Aebischer, M G Bianchetti.   

Abstract

In adults the calcium antagonist amlodipine given once a day has proved to be an attractive addition to the antihypertensive armamentarium. The present report describes our experience in 43 paediatric outpatients (26 boys and 17 girls, aged between 1.1 and 19, median 9.8 years) with chronic kidney diseases. The patients were given amlodipine for 16 weeks as part of their antihypertensive treatment. Before amlodipine arterial pressure was 150 (142-163)/90 (84-95) mm Hg (median and interquartile range). Six patients withdrew from amlodipine because of oedema, flushing or headache. In the remaining patients amlodipine 7.7 (6.9-9.4) mg/m(2) body surface area once a day significantly decreased arterial pressure by 17 (13-22)/10 (7-13) mm Hg. The efficacy of amlodipine was more pronounced in girls than in boys. No changes in heart rate, body weight and circulating haemoglobin, sodium, potassium and creatinine were noted. In none of the patients circulating potassium, sodium or creatinine changed by more than 0.5 mmol/l, 5 mmol/l respectively 20%. In 11 patients concomitantly treated with cyclosporine the dosage and the trough-level of this agent were stable throughout the trial. In conclusion the present experience in paediatric outpatients with chronic kidney diseases supports the view that amlodipine is an effective and rather well tolerated antihypertensive drug when given once a day.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11439313     DOI: 10.1038/sj.jhh.1001203

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  8 in total

1.  Bioavailability of a pediatric amlodipine suspension.

Authors:  Dorothy A Lyszkiewicz; Zina Levichek; Eran Kozer; Yaron Yagev; Myla Moretti; Marjie Hard; Gideon Koren
Journal:  Pediatr Nephrol       Date:  2003-05-07       Impact factor: 3.714

2.  Cyclosporin enhances the tendency towards oedema and flushing noted on dihydropyridine calcium channel blockers.

Authors:  R O von Vigier; E Fossali; A Edefonti; B Vogt; M G Bianchetti
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

Review 3.  Pharmacologic treatment of chronic pediatric hypertension.

Authors:  Renee F Robinson; Milap C Nahata; Donald L Batisky; John D Mahan
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

4.  Efficacy and safety of prolonged amlodipine treatment in hypertensive children.

Authors:  Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2005-03-23       Impact factor: 3.714

5.  The role of calcium antagonists in patients with chronic renal failure.

Authors:  Karl Heinz Rahn
Journal:  Pediatr Nephrol       Date:  2005-06-22       Impact factor: 3.714

Review 6.  A review of calcium channel antagonists in the treatment of pediatric hypertension.

Authors:  Shobha Sahney
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

7.  Effect of obesity on response to cardiovascular drugs in pediatric patients with renal disease.

Authors:  Sherif Hanafy; Maury Pinsk; Fakhreddin Jamali
Journal:  Pediatr Nephrol       Date:  2008-12-13       Impact factor: 3.714

8.  Effect of renal function on antihypertensive drug safety and efficacy in children.

Authors:  Kevin M Watt; Debbie Avant; Jennifer Sherwin; Daniel K Benjamin; Christoph Hornik; Daniel K Benjamin; Jennifer S Li; P Brian Smith
Journal:  Pediatr Nephrol       Date:  2017-08-04       Impact factor: 3.651

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.